• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Optilast
    / Megapharm

    Active Ingredient
    Azelastine (HCl) 0.05%

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Eye Drops

    6 ml X 0.05%

    not in the basket chart 51961 15133


    Seasonal allergic conjunctivitis: The usual dosage in adults and children 4 years and older is one drop in twice daily that can be increased, if necessary to four times daily. If allergen exposure is anticipated the drops should be administered prophylactically, prior to the exposure.


    Symptomatic treatment and prevention of seasonal allergic conjunctivitis.


    Proven allergy to any of the components of the product.

    Special Precautions

    Optilast eye drops are not intended for treatment of eye infections.
    Benzalkonium chloride may cause eye irritations. Any contact with soft contact lenses should be avoided. Contact lenses should be removed before using this product and should not be reinserted before at least 15 minutes after instillation of the drops. It is known that this product causes discoloration of soft contact lenses.

    Side Effects

    Mild transient irritation of the eye after application. Rarely, a bitter taste and allergic reactions (such as rash and pruritus).

    Drug interactions


    Pregnancy and Lactation

    Pregnancy: There is insufficient information available to establish the safety of azelastine in human pregnancy. At high oral doses azelastine hydrochloride has shown to induce foetal death, growth retardation and skeletal malformation in experimental animals. Local ocular application will result in minimal systemic exposure (plasma level are in the pictogram range only). However, caution should be exercised when using Optilast eye drops during pregnancy.
    Breast feeding: Azelastine is excreted into the breast milk in low quantities. For that reason, Optilast eye drops is not recommended during lactation.


    No specific reactions after over dosage in the eye are known, and with this route of administration, over dosage reactions are not anticipated.
    There is no experience after administration of toxic doses of azelastine hydrochloride in humans. In the case of overdose or intoxication, disturbances of the central nervous system are to be expected based on the basis of results of animal experiments. Treatment of these disorders must be symptomatic.
    There is no known antidote.

    Meda Pharma GmbH
    Licence holder